Earnings call transcript Q2 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Tom, and I will be your conference operator today. At this time I would like to welcome everyone to the Amylyx Pharmaceuticals Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. advised request. call be at being Please company's the instructions] that is this recorded [Operator

now to Communications. would Head I like of Lindsey over Investor Allen to Relations and Please ahead. turn go the conference

Lindsey Allen

Jim and Officer. Margaret second XXXX are Olinger, Commercial our Josh our afternoon to the Justin and and me quarter thank us Chief earnings. joining Good today Frates, for Klee, Financial discuss Cohen on With our Chief call you our Officer; Co-CEOs;

remind to that everyone any we Litigation Securities facts provisions begin, beliefs, like Before expectations are presented of made call Act would make Reform plans we this are are and harbor information of current made are that the or on that I XXXX. statements historical our pursuant Private based and safe forward-looking to on statements not the

but respect with Actual outlook clinical the results include differ strategy our our statements regarding to could events and business RELYVRIO are expected regulatory not implied with to our financial expressed ALBRIOZA, any performance. developments future our as set materially the and with factors, filings in we those a expected recent uncertainties and by statements various and thereof, or any trial other including limited forward-looking expectations and These timing and and from forth most may make our result the those SEC of filings statements risks, that other SEC. and

reliance statements on cautioned law. statements forward-looking Amylyx by undue are any place update these any obligation such required You unless not to disclaims and to

will call Now, turn to Justin. the I over

Justin Klee

diseases. with day suffering our RELYVRIO respectively made In and quarter, mission US and advancing neurodegenerative bringing Canada significant caused and in and of ALS Lindsey, afternoon. the good we you, second other ALS the one in Thank ALBRIOZA by ending to people and progress the

treatment, and raising with proud September. who we deepening of to working goals been goals Care RELYVRIO about approved our prescribed included full the our to with are people helping and -- ALS with our on following support Amylyx has We of to people understanding physicians have continued market. outlined, These approval insurers ALS living program, patient RELYVRIO our educating and who entire that last awareness RELYVRIO, Team provide deliver team, of access the through incredibly the FDA

me through you Let walk our progress.

organization commercial strong and the and strong to is awareness RELYVRIO quarter. off saw second Our as we in a demand raising by start the steady about evidenced educating

As over XX, people XXXX. on roughly of up June X,XXX XXXX, in just from people on the roughly the XXXX X,XXX and at end X,XXX March of XX, as there US, of were RELYVRIO RELYVRIO

As for living an nearly insurance coverage and living rapid we formal broad policies more adoption ALS down supportive. covering and year have time quickly. people able of written in prescribed have this days that RELYVRIO are our this quarter ALS earnings little quarter with and fourth XX and a been call. over covering RELYVRIO in around between have second from first when been prescription the start now metric majority XX the with people published Insurers of a XX has shared and to days was are been shipped quarter, and vast RELYVRIO, policies all the The days about being average being on therapy

anniversary one-year Health our with in reached we conditions approval June. Canada, to Turning of the Canada

achieved have we community. Canadian our progress, reflect we are with ALS on the behalf on of pleased As what we

vast the that Canada. lives majority insured in we in announced In and we ALBRIOZA publicly of last share place expect the ALBRIOZA covered end of to are pleased for today insurers major by to year, that in coverage August, of quarter private be fourth we all Canada the

that ALS globally support our invest our bringing people pipeline opportunities in both has RELYVRIO living to advance commercial to The more launches early mission. us with success our of enabled and

approved. We on expect in a execute opinion EU and a successful continue if fall in launch prepare the to MAA to CHMP from our the final

new We the to this diligently are topline course, mid-XXXX. our excited And initiate PHOENIX AMXXXXX we in ORION supranuclear year. complete progressive work Phase to of trial to anticipated X clinical continue of with results palsy in later trial

and In are we so organization. far in proud our progress summary, of can an about achieve what we XXXX excited as

on we clear We have mission a and executing are our goals.

performance. turn Margaret the to on commercial call update over our I'll to an provide now

Margaret Olinger

our on In priorities. Thank we you, make significant continued the Justin. to second three quarter, progress key

our trial drive educating first with as people includes function in RELYVRIO drug awareness to demonstrate the the clinical longer among well statistically that benefits and a analysis. adults is a of and is survival only benefit effort and educate approved to about significant term benefit as a RELYVRIO post and with first This for The living clinicians. the ALS hoc ALS and

on reminder, a England XX X.XX the scored the placebo than after scale that demonstrated treated data weeks, RELYVRIO group. As of Medicine clinical published higher on average in trial ALSFRS New Journal the with points participants

Even score to a in change indicate of ability or living eating, independently activities in including person's dressing, bathing, difference one-point walking. a ALSFRS a daily can significant with the function

of placebo, Participants trial, it survival with benefit. RELYVRIO longer starting participants were they the a started and treated than months six RELYVRIO means saw for that both on on at clinical which earlier the start greater

people those in build diagnosed from for ALS both and quarter, at that During newly been have RELYVRIO demand to interest for a steady living continued and who years. are pace with the second

of people States. As United were XXth, on efforts, as in RELYVRIO a result roughly our the there of X,XXX June educational

We so are very many have gained people to treatment this new that access important quickly. pleased so

all and of Prescribing that fairly XX prescribers us. just with centers over demonstrate few of of concentrated a remains end ALS mostly me quarter. at major representing RELYVRIO approximately growth half let Now, through our progress metrics at the run ahead opportunities prescriptions key the

this as centers. prescribers by an have growth message bring relationships and We interest for our are within these ALS key encouraged level and our that group to believe the among opportunity of we we more deepen

top centers have at approximately ALS key to of of RELYVRIO X% end nearly launch. since second prescribed the XXX the all the prescribers least By the XX% and of quarter, US

prescribers within on key are focused ALS and education centers. driving top our and on We awareness deepening and the penetration

have a large In expand more growth efforts prescribers educational for as group this outside of broadly. and of top our addition, opportunity outreach we we untapped

Our that second and who possible. as with every eligible engaging priority work RELYVRIO help efficiently quickly to to benefit person has is as ensure from could payers treatment access

our published Consistent insurers provide of that with policies. of is lives the end just significant outlined, coverage broad all vast estimates RELYVRIO. majority our into formal launch. ALS-covered three targets representing these by a This the accomplishment second suggest we previously insurers the had to US The access quarter, commercial nearly quarters

priority clear people's ALS have positive as and obtaining possible been have their positive RELYVRIO have through people to and treatment people who with includes experience as can. eligible best access Amylyx. quickly therapy journey we with Our living with interactions facilitating is prescribed RELYVRIO RELYVRIO get organized process interactions ensuring This optimizing as an third ALS clinics to

between team being being on In XX done this coverage. shortened and increase the tremendous Our shipped. job insurance about the in of to RELYVRIO the by second was has a a days, increasing quarter, prescription facilitating process, written aided speed the average timeline

therapy work ALS as who expeditiously Our with to on been living people RELYVRIO prescribed have team get quickly continues as possible. to

ALBRIOZA Turning Canada, remains in interest to our in high. launch

on efforts. public significant insurance made our have progress coverage We

and ALBRIOZA in We the By reimbursement for provinces expect majority insured vast of Alberta be are publicly Canadian Brunswick end five to thrilled ALBRIOZA. August of most in Columbia, recently lives the public Ontario, we coverage announced that of Quebec, British place New Canada.

foundational becoming And goal a are believe ALS is to ultimately treated. people the we RELYVRIO way Our ALS. change therapy is living with for

education As RELYVRIO into team with about third and remains ALS among our awareness people living we and move clinicians. on the driving quarter, focused

I turn will the quarter. our call now to for second to financial over the discuss Jim results

Jim Frates

we to in strong the view, remains see from encouraged interest quarter. and business Thanks, by the a second community continue financial strong. Margaret. our point demand We're the From of ALS

revenue for million for the $XX.X States. the the revenues million product of Net revenue quarter of that product were United of compared from net vast with to first XXXX, majority the coming quarter, $XX.X

adjustments to were true-up nine the the estimates in that XX% normally based Gross approximately reserve quarter, favorable than would a of is months. second in anticipate experience to actual our the we the due little net on lower quarter which in past

discounts of seen we've net two to $X.X range. as similar end levels for anticipate Cost of quarters. be XX% to of with X% Inventory sales revenues at product quarter is range what million gross Going that were net in expectation weeks roughly quarter were of XX% remain previous XX% sales specialty will approximately forward. pharmacies, in channel to inventory we forward, in the for in expected, X% our the the COGS will at to and the going the

in sales not will royalty Note ALS this any fully additional royalty all our forward. and that related we remaining expenses to obligations expensed be incurring going of quarter

receiving modeling on it assistance XX% purposes, of mind either keep program. in patient the are or for through roughly free, interim our people For that access program RELYVRIO

Research were quarter. and million the expenses development for $XX

You should for million R&D $XX per the the remainder to expect in quarter to expenses the be range million year. $XX of

that in trial of in range will move is As we Phase patients expectation higher in new QX our R&D start as PSP. this call, year the expenses our this X end outlined toward our later we enrolling

or on expenses call. with quarter the run and our quarter, line that were quarter we general million in first for Selling, $XX mentioned SG&A million $XX.X rate per administrative the

We These of results range million $XX.X profitability. an led We in in expenses income, our generated in bottom for the continue to representing this to second excellent of expect row line. a SG&A quarter remainder year. net the

our financial and treatments execute our we deliver throughout quarter perspective, debt. positioned execution the resources our neurodegenerative diseases strong to We're short-term the investments have line. and results well line, pleased organization. more From grow bottom We're ended million mission. invest $XXX.X cash and provide our much pipeline with a to on in with we capital top zero and needed the disciplined our with we the Finally, on of need for to

the turn discuss to our now call programs. to R&D Josh I'll over

Josh Cohen

Jim. Thanks,

help benefit lead pathways endoplasmic to and stress neurodegeneration. that have in ALS stress could we the We and was of AMXXXXX goal our connected believe in or originally it neurodegenerative other diseases. to two dysfunction AMXXXXX ER target When reticulum mitochondrial developed demonstrated central

study in leaders, key last announced was XXX study Phase intend called and participants PSP call, a and approximately planned people in we enroll year it well-powered academic initiate pivotal we PSP a with Orion global on will that advocacy and groups. later Orion. X with to collaboration living As designed our is global this

well-known to be hallmarks disease-modifying progressive help. but PSP to and respect no are swallowing that include for treatments PSP function. disability disease rare progressive imbalance, speech walking movement, that clear with AMXXXXX might neurodegenerative eye hopeful fatal There is able with cognitive we a currently and and recognizable are and clinical and

supporting genetic findings, characterized in primary is role disease. and PSP for a as tauopathy, tau pathological a with this

a X Phase data, the action AMXXXXX's proposed of the and upstream AMXXXXX both that tau lowered cerebrospinal of that are in Alzheimer's indication ORION fluid demonstrated excited tau this a and PEGASUS significantly of mechanism We trial. clinical people plasma in hosted our pathways leading with placebo-controlled the and trial Given tau PSP. targets primary for in recently aggregation X XXX total with Professor we webcast investigator Dr. which pursue expert Gunter disease, Hadinger, Phase to PSP

part of overview webcast, an and Phase into we rationale design. studying the trial insights As for shared scientific X PSP of the the in AMXXXXX

Additionally, Dr. in if chance should we AMXXXXX available the the IR event. a you perspectives it, website be replay join with our use tau living of and listen and the is treatment this the role on in the Events his Hoglinger to have PSP didn't encourage landscape, us section in for potential provided people approved. of live it to to PSP you to disease The

adulthood. pursuing syndrome to Wolfram also syndrome in are study neurodegeneration In PSP, program often disease failure resulting diabetes, this ataxia, in deafness, Wolfram to and called is in a another we early death that addition disease leads multisystem HELIOS. rare a blindness, in rare exciting

in Our AMXXXXX of vitro in syndrome together of studies Dr. Wolfram at Washington Fumihiko R&D Urano team conducted vivo roughly and four leading in researcher with a years University.

we And discussed Journal provide in Several disease study These in as the line papers Clinical currently we this stress. results Investigation we of studies top participants past, next disease year. of expect which some have as Insight. believe characterize results data prototypical have which guide future the of key to and were a enrolling published promising the is studies ER will

in in believe continue ALS, cellular ultimately order going it's and also neurodegenerative broaden pipeline. implicated approach, disease disease ALS to a We combination targeting cure take a to that to We for pathogenesis. multiple pathways find our

to targeting our continue through progress CalpainX, We IND-enabling studies. AMXXXX, antisense oligonucleotide

future. advancements MDA, and We in other candidate the present presented on in have We're data AMXXXX on excited conferences. this at more data and pipeline NEALS, our the to TIDES

are ALS we of our are work closing, doing team's proud behalf community. the the that In we on progress of and

ALS position our other which strong with in people in launches for a support to to our ALS treatment continue find to living diseases. invest very progressive are pipeline options in allows us new neurodegenerative We financial and relentlessly and

we'd take to please Now, happy call Operator, the your up Q&A. open be questions. to

Operator

from And comes Instructions] go ahead. Please the question Corinne Jenkins Goldman first [Operator with Sachs.

Corinne Jenkins

Good compliance emerging be here. are And first, afternoon my there. with with respect what share Are everyone. you trends with Maybe ahead I'll seeing seeing just to it the reason primary you follow-up just rates? discontinuation; you discontinuation any and respect to would for helpful whatever go

Margaret Olinger

for Maybe a as just very question. Thanks on patients the reminder, on therapy. start, much net report to we

of inclusive is this So any discontinuation.

any would participants see the a we're Approximately of say roughly long-term on going a is eye pleased which an at X,XXX again, a commercial continue as really XX% to really trial, and we expect say a net the drug, setting. launch. reminder, as would at patients six-month clearly shift But to close this end that on trial. patient early I time. in of point the trends in where too the point serve are on maybe to keep this CENTAUR over ability to close very to I reference in QX. we're it's our was tracking RELYVRIO to We with of mix remained area the our But terms

Justin Klee

side compliance reasons. of the the On

We're they're going XX% in find seen in different as are on to with disease of well. discontinuation, we've for compliance. of terms People the reasons ALS in rare many range terms side, drug varied. So in drugs, compliance that range XX% most the And things. you'll through

progression, and of as expected in course, is disease death the Of one ALS ones more is common certainly which well.

Corinne Jenkins

Thanks.

Operator

comes Please next of Bank The question go Geoff ahead. from Meacham America. with

Geoff Meacham

I on had for quarter. couple. Hey guys. the Thanks the question. Congrats a

the you ask with there? I process here. for how the CHMP how or reexamination success to wasn't sure protocol process. first maybe be rate EU, next could view the guys you The And is I that now. wanted view us help just the what steps the

time be And the to evolved you BD. deployment. you deals, done second maybe profitable? much. capital some that's some Thank question over is as how ask to know very have just you I to I sustainably related want guys look

Justin Klee

Sure.

on with course, pre-specified negative So in -- on basis approval we've primary slowing opinion. so of for ALS conditions Canada. approval and And and US opinion. of progression in study adopted we've previously, initially the I a as a EU approval And our placebo-controlled rate the the on We data, -- strongly shared survival. disagree outcome, the overall is FRS, the randomized CHMP, the also meta to our showing that EU observed think on of Health difference by that led FDA a that

this in have we But a package our CHMP. So that we to approval. view, should course, believe of ultimately, data support up is

submitted got that the negative roughly That's We application. and submitted assigned the a apertures after for four-month shortly reexamination. which opinion. we under, are So two review new process we

we'll this back end regarding opinion. can that you of the So hear year, near that expect

of capital to BD, talk -- and pass terms to deployment Jim. I'll In I'll potential

Jim Frates

ALS gratifying. have And that is vast our Yes. result Geoff. I dearth in the a area -- that this early with people of had mean, profitability Thanks launch I clearly need the living ultimately the far. options this and in on in is patient of so this -- think direct very

that we're proud filling be So of very need. to some

the what's think States is still the I launch focused Canada, working middle We've the see happen to a have what in know, the obviously potentially plate would our we the Japanese drug. say started forward right You take United I with on to and this through the and we to with now, of continue too next really off to launch on we're thing other places year. interacting too hopefully looking other and Europe world are around and in going can where in

it say is around PSP doing. our the With I'd now focus. our watch we're first that Wolfram program program and here right ongoing

also have I business But hopefully with term. that in our term, over some to Now opportunity longer that development here to robust right pretty I longer high think the our business on launch word watch said think, and invest grow a the as think a be and But able then for top-line, potentially I the focus. we with pipeline. standard programs. new in now we'll we is bottom-line the grow the And have I do we're

Geoff Meacham

Thanks, guys.

Josh Cohen

You bet.

Operator

And question comes the Evercore. next with from ahead. DiFiore Please go Michael

Michael DiFiore

for and quarter my Hi, taking for Congrats me. question. so thanks on guys. Two the much

this the is this do my press at I the little with in of rates. want the passage the the mean more Now patients And to drug you of have you what have XQ this better discontinuation months of bolus follow-up of early on you the these I at provide any some at point? six a commercial on year time drug therapy them have be patient patients received still to among least on size of bit to again of any for to among who XQ? percent -- would point last patients are just presumably Would as are in color been sense started now. able

Margaret Olinger

Yes. with Maybe I'll regarding bolus. just start the question your

to diagnosed years. very be interest pleased I people for the at diagnosed both think and and patients RELYVRIO, newly that continues includes in of a strong living importantly to pace who ALS continue mix We a as with have and been for demand and be many

in in end on X,XXX just the X,XXX patients QX. roughly QX QX, and from of patients therapy at roughly we up had net Again over X,XXX

our been some obviously to for really on which really point time. a need really community a ALS mission we've and unmet for in foundational believe this we is that this and in focused therapy high meeting at So patient is become what time RELYVRIO starting

opportunities us. which us growth ahead different opportunities of important far see we is equally the As several to as

mostly prescriptions us. the encouraged prescribers opportunity the large where beginning We're for among growth level representing concentrated prescribing also major a of the group launch we centers quarter. XX remains believe about our this that was that focus the at the of ahead RELYVRIO and really First half ALS at have this of all interest of with

in our part. bring more I relationships with we be which And and I messaging an to As key those more is prescribing our centers. important prescribers think prolific importantly much prescribers deepen those think within their

And second outside for growth we this a untapped large group. opportunity have really of

moving at expand important patients the to fairly we're quarter. focused to on be for question of cohort the indeed, patient critically going to that everybody again, it's of As and to launch. And I paradigm centers progressed those net aware treatment continuing many change maybe more in outreach on believe mentioned, that launch were function at ALS the for that your therapy we a important early key been broadly efforts and who But first the product on just survival believe think started second who because numbers we reflect only RELYVRIO We're and I heavily we the have we forward. is answer first-and-only discontinuation, clinical can on trial reporting educational to is demonstrated have our both it's on. really

I we're change the time. over going see to So the patients dynamic of think

there. really So it's any a to little give too early trends

Joshua Cohen

we Margaret real so I'll central -- that, Yeah. different approximately shared world drug. is seeing again of And the And what I that. as study we're one But some study thing, in on remind XX% -- that study from in not of completed think people well earlier

Michael DiFiore

much. so you Thank Great.

Operator

Marc with question Leerink go Please Goodman comes The ahead. from Partners. next

Marc Goodman

Yes. Hi.

question getting willing any mentioned the you can confirm comment you are drug. July? And you what to about then XX% just of -- free secondly, in seeing saw First you you're trends kind patients is of make are

right and your in patients to clear the that Just X,XXX that were numbers on be about everything? that. calculation Thanks. in is included be you and the provide it's gross-to-net just to talking I clear all that, in you want XX%

Jim Frates

XX% Yeah. is that Yeah, are Hey, receiving of free Marc, the patients it's included. Jim. drug the

is in the getting free therapy yeah, it. on the right? drug the patients. included me, And Those net those drug would COGS, excuse of all patients in not gross-to-nets June. So free in are and be are actually any at included drug end you're for given -- You've sales the XX%

So that's in the goes co-pay gross-to-nets free like drug in assistance that clear assistance on Any to that things goes pay patient what just COGS. that. or terms of be we in the

in our our moving results the specifics our our giving on quarterly won't all I forward. finally, is under quarters of belt, I July for chance we'll see business comment then -- what think to at three starting terms QX. we're we like a And this get with to July stage. when on July, report But But think business now trends is be we

Marc Goodman

Thanks. Great.

Jim Frates

bet. You

Operator

question comes next go Suvannavejh Mizuho. from The Graig Please with ahead.

Graig Suvannavejh

on quarter. Thanks so the much. Congrats

to the on way that's you kind my the to to targeting And then can of any to are there any that -- two expansion refill on prescription about could context One that put people center new beyond be Thanks. versus that of or or seem you a efforts setting. ask outside to portion follow-up provide another evolved? I'm Do get of prescribers hope into that the Just trends? you you're get question you go color questions. And maybe curious ALS trying ALS can ALS if is perhaps the centers. trends Any you color provide at. metrics have how and

Justin Klee

start and too. join I'll Margaret in then So have

three quarters we're launch. again, into So

that We the like many, about. helping. very that I to mean, ALS which we'd as of But that's well. of with have end help we're roughly many on X,XXX treatment more people we're QX that people net as pleased X,XXX there's people means

And historically unique. And been treatment think options. of huge are the is constantly disease, it's few mission we ways ALS it's large a I there need. there's because hand. I But unmet in the rare have And all think here medical a reminded market many at

think then Margaret ALS broaden way to the focus about continuing and our is we've look specialists, I on so to that thought as business, sharing, out. the And was to

focused as is people think we where so I prescriptions as at well. our we're the And our have where look prescription seeing numbers,

details on that. I'll any more Margaret, then to share invite And you

Margaret Olinger

Yeah.

launch decision the the focus to I where As ALS strategic centers think patients are at actually which indicated key on focused majority ALS the right treated. we've was of heavily

patients a outside treated to need multiple However, reasons, there they number it's go a get ALS transport, -- to see can't time that either centers care. typically quarter they can't there's reasonable the are every for there and also at they of multidisciplinary of ALS

Community equally number be call that a educated to important we our we are and those, expanding our continuing and General to and out B are where targets. of reach Neurologist, that's A are Tier And our we're There or increase to what penetration focus.

And we're just going can to continue this to that benefits ALS work on patient us an that about for significant expansion patient serve is moving we forward, that every to educated because it's optimally. the community really important to treats who be RELYVRIO bring able physician

Operator

from [Operator And next question Please go Wainwright. H.C. Ghosh comes Instructions] the ahead. Ananda with

Ananda Ghosh

guys. on congrats Thanks giving quarter. time the also, for me and Hi

PSP. two on for ALS program and have questions I the So the one

The question is keeps be. question which community basically of coming first some the industrial that from would the and

can what -- ALS then a RELYVRIO off and follow-up is of and to on accelerated then, PSP. study it confirmatory So be from it initiate I the on a if for market? says, would question that program great. clarification PHOENIX approval If then, a And FDA pull have the any required process

Justin Klee

a be which mean, be And authorization it's and Notice In Compliance no a that there if the the would expectation our would And also condition conditional PHOENIX. the in condition is thank there's Europe, marketing There's with there an first, Canada, you Ananda. of again, PHOENIX NOC/c an And it approval question, full FDA a Conditions. study. yeah, is Sure. for approval. means, I of

the community, run results. But study. to PHOENIX study. results a it's FDA forward continue very And a an year. to think from approval. mid-next have are looking perspective, those we We'll full those FDA I powered we highly the So and ALS That's

Ananda Ghosh

The patient stability. next the question remarked you. signs Thank is that the quarter had you might Great. show last that of

as still is in segment -- terms is the growth with valid ahead So, for remains that of RELYVRIO? we think still it

Justin Klee

us I to think you're it's critical bringing the all area on But and exciting. up is in And question for a think tell. new neurodegenerative it's too Well, patient really, it's early of disease. I'd one a responses say, so, I still really really

Now, effective faster, little whether we people to certainly but was or genetics specifics, progress whether the environmental disease, those really been ask early some because do haven't we're at whether in some to evidence-type you very, real-world and to due had something I that very treatment. can start was study, just -- questions we those progress too their are able questions that to is it's others of to we're just haven't But or we to because But excited effective this saw seem still to treatments. more who time, that we know. approaches of when it's have their due of, course who ask, critical Centaur the very asking think that and certainly, sorts really, you an

Ananda Ghosh

that has is the of rate high some disadvantages. dropouts. natural so a we very saw And general in couple PSP One kind Thanks. Right. PSP. studies history on my last question of Based data, is on of

to And trials. mostly historical and PSP in some of the cognition the fails depression at scales least

how design? incorporated have been III these has what you your And So thought on into trial your Phase kind it? of

Josh Cohen

Yes.

importantly more on Gunter Dr. on published our more that's in-depth and of shared Professor recent So, clinical upcoming call that a website, even we did, view we much a PSP trial. probably and Hullinger shared our

when So, in primarily a of primarily tracks the on is motor our -- PSP. would trials, several of PSP studies. approximate error a progression approximately variance pretty you're these over is quite found what's PSP and in a past I cognitive scale than functional, are scale. the an that PSP consistently trial, rating scale PSPRF, study of designing in the kind outcomes and tight small The based rather XX-point studied been year kind This we with rating a say, pretty

studies, our previous in diseases. not as beyond compared the previous has have view is quite in is the power has shown in actually where studies most been what from And other you good this Dropout might space again, is not a been neurodegenerative diseases. and to neurodegenerative

we So, detail. lot again, very take have feel and into a indication say go is in have where people design, we overall to that we we to into. and scientific overall, webinar -- the AMXXXXX I'd more But this encourage great listen great that rationale a a I great strongly this to trial say I'd a

Ananda Ghosh

much. very Thanks, Great.

Operator

This the over session. turn conference to for our question-and-answer any back conclude I'll will closing Justin remarks. Klee

Justin Klee

today operator the Well, for thank support. thank all for us you on you your and and call joining

hope, a good you evening. joining all Thanks have us. we for So

Operator

now The for Thank has presentation. you attending today’s concluded. conference

You may now disconnect.

Amylyx Pharmaceuticals (AMLX) 10 Aug 232023 Q2 Earnings call transcript